Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.
about
γδ-T cells: an unpolished sword in human anti-infection immunityγδ T cells in cancer immunotherapyProlonged antigen survival and cytosolic export in cross-presenting human gammadelta T cellsExpanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions.Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersAzathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.γδ T-APCs: a novel tool for immunotherapy?Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".Potential Use of γδ T Cell-Based Vaccines in Cancer Immunotherapy.Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity.The Antigen-Presenting Potential of Vγ9Vδ2 T Cells During Plasmodium falciparum Blood-Stage Infection.Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model.In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.EBV transformation induces overexpression of hMSH2/3/6 on B lymphocytes and enhances γδT-cell-mediated cytotoxicity via TCR and NKG2D.
P2860
Q26994963-E175BC53-CBA2-441D-95BF-C247A4E8E57EQ28068988-39490F45-4873-4445-AE77-22941B1AE6C8Q33928383-3F8C2B46-7EB1-4423-9EA5-BF76C9028AAEQ33938500-C4F3F017-8456-4E57-88F4-2241E0E92401Q34372167-36B29E38-959C-4EAC-92C3-BF719D348109Q35738744-69190F1B-1B23-4937-BA13-3DF88FB75A1FQ36040498-8322D853-F4DE-4C26-AE3F-732AA4AD78DDQ37751873-702A6159-3685-4F29-9937-3B7D9D89203EQ37875768-75059E5F-B172-4218-ADBE-7B5BBB7DEDBAQ37919880-D5F2684C-12D0-46D2-B851-69B9548F98D7Q38265506-F22CB822-4A09-4E7F-AAFE-F2C9E2920B02Q38883322-5D55CC8A-A0F0-4E00-9F6A-E32A1376B335Q39079775-B182F30B-094E-4EDB-BE00-F29DA07414D3Q39472050-5C16F5E9-CC51-453B-B338-18E3698694BDQ40146526-78831183-89DC-4A14-9888-26FBA4B254BFQ43057295-7710A926-78EE-4F7A-97AF-09605CF4175FQ52669885-329D9323-DA70-4D02-9452-6EA9B6E3C025
P2860
Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@ast
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@en
type
label
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@ast
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@en
prefLabel
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@ast
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@en
P2093
P2860
P1476
Activated human gammadelta T c ...... l for immunotherapy of cancer.
@en
P2093
Anna Hansmeier
Catherine M Bollard
Claudia Rossig
Guido Bisping
Heribert Juergens
Lena Varnholt
Sibylle Pscherer
Silke Landmeier
P2860
P304
P356
10.1097/CJI.0B013E31819B7C30
P577
2009-04-01T00:00:00Z